The US Food and Drug
Administration (FDA) has approved
Topamax (topiramate) for migraine
prevention in adolescents aged 12
to 17 years of age.
The FDA said this was its first
approval for a migraine prevention
drug in this age group.
The drug was approved for
migraine prevention in adults in
2004.
FDA Center for Drug Evaluation
and Research Division of Neurology
Products deputy director Eric
Bastings said adding dosing
and safety information for the
age group to the prescribing
information would help to inform
health care professionals and
patients in treatment choices, as
migraines could impact school
performance, social interactions
and family life.
A clinical trial of 103 participants
established the safety of Topamax.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Apr 14
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.